Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netupitant + palonosetron for opioid-induced nausea and vomiting in cancer pain
ChiCTR2400092551Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of netupitant and palonosetron in Opioid-induced nausea and vomiting (OINV) and cancer pain, sponsored by West China Hospital of Sichuan University. Primary endpoint: Complete response rate of opioid-induced nausea and vomiting. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
netupitantpalonosetron
03
Conditions
Opioid-induced nausea and vomiting (OINV)cancer pain
Beyond the preview
Go deeper on ChiCTR2400092551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092551.